North America Oral Anti-Diabetic Drug Market Size (2024 - 2029)

The North America Oral Anti-Diabetic Drug Market is anticipated to experience growth over the forecast period, driven by factors such as the increasing prevalence of diabetes and the impact of the COVID-19 pandemic. The pandemic highlighted the vulnerabilities of diabetes patients, leading to a greater reliance on diabetic medications to manage blood glucose levels. Additionally, the shift towards remote healthcare and the easing of regulatory barriers have further supported market expansion. These elements collectively contribute to the anticipated growth in the market size during the specified period.

Market Size of North America Oral Anti-Diabetic Drug Industry

North America Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 18.76 Billion
Market Size (2029) USD 23.60 Billion
CAGR (2024 - 2029) 4.70 %

Major Players

North America Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

North America Oral Anti-Diabetic Drug Market Analysis

The North America Oral Anti-Diabetic Drug Market size is estimated at USD 18.76 billion in 2024, and is expected to reach USD 23.60 billion by 2029, growing at a CAGR of 4.70% during the forecast period (2024-2029).

The COVID-19 pandemic had a favorable effect on the market for diabetes medications in North America. Diabetes and uncontrolled hyperglycemia enhance the risk of serious illness or death in COVID-19 patients and are risk factors for poor outcomes. The COVID-19 problem makes the immune system weaker more quickly in people with diabetes, who already have weakened immune systems. Compared to healthy persons, those with diabetes are more likely to experience significant complications.

Pharmaceuticals known as diabetic medications were created to stabilize and regulate blood glucose levels in diabetics. Diabetes is frequently treated using diabetic medications. Diabetes patients infected with SARS-CoV-2 during the COVID-19 pandemic may be treated with diabetic medications. Up to April 2022, the United States had the highest number of COVID cases in North America, around 82 million, and the highest fatality rate. The pandemic emergency has led to an increase in remote patient and provider care and the removal of many enduring regulatory impediments.

In recent years, diabetes prevalence has alarmingly increased in the North American continent. Diabetes rates are at an all-time high in developed nations like the United States and Canada, largely because of lifestyle modifications. Many health issues are related to diabetes. Diabetes patients need to make several adjustments throughout the day to keep their blood glucose levels within normal ranges. For example, they may need to administer more insulin or consume more carbohydrates.

As a result of the aforementioned variables, it is projected that the market under study will expand during the course of the investigation.

North America Oral Anti-Diabetic Drug Industry Segmentation

Antihyperglycemic medications are taken orally to lower blood glucose levels. They are frequently employed in the management of type 2 diabetes. The North America Oral Anti-Diabetic Drug Market is set to witness a CAGR of more than 5% during the forecast period. The North America Oral Anti-Diabetic Drug Market is segmented into drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists, Sodium-glucose Cotransport-2 (SGLT-2) inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides), and Geography (United States, Canada and Rest of North America) The report offers the value (in USD million) and volume (in Units million) for the above segments.

Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028)
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Geography
United States (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Canada (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of North America (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Need A Different Region Or Segment?
Customize Now

North America Oral Anti-Diabetic Drug Market Size Summary

The North American oral anti-diabetic drug market is poised for significant growth, driven by the increasing prevalence of diabetes and the rising demand for effective treatment options. The market is characterized by a robust pipeline of innovative medications and a strong focus on research and development by major pharmaceutical companies. The COVID-19 pandemic has further underscored the importance of diabetes management, as individuals with diabetes are at a higher risk of severe complications from the virus. This has led to an increased emphasis on remote healthcare solutions and the removal of regulatory barriers, facilitating better access to diabetes medications. The market is dominated by key players such as Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals, who are actively engaged in expanding their product offerings and enhancing their market presence.

The market landscape is also shaped by the widespread use of metformin, a first-line treatment for type 2 diabetes, known for its efficacy, safety, and cost-effectiveness. Metformin's broad acceptance and prescription rate highlight its critical role in diabetes management. Additionally, the introduction of new drug classes, such as sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors, has expanded treatment options for patients. The market is further supported by initiatives to make diabetes medications more affordable through discounts and insurance coverage. As the diabetes population in North America continues to grow, the demand for oral anti-diabetic drugs is expected to rise, driving market expansion over the forecast period.

Explore More

North America Oral Anti-Diabetic Drug Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028)

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha-Glucosidase Inhibitors

        1. 2.1.2.1 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 receptor agonist

        1. 2.1.3.1 Bromocriptin

      4. 2.1.4 SGLT-2 inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

    2. 2.2 Geography

      1. 2.2.1 United States (Value and Volume 2017-2028)

        1. 2.2.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      2. 2.2.2 Canada (Value and Volume 2017-2028)

        1. 2.2.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      3. 2.2.3 Rest of North America (Value and Volume 2017-2028)

        1. 2.2.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

North America Oral Anti-Diabetic Drug Market Size FAQs

The North America Oral Anti-Diabetic Drug Market size is expected to reach USD 18.76 billion in 2024 and grow at a CAGR of 4.70% to reach USD 23.60 billion by 2029.

In 2024, the North America Oral Anti-Diabetic Drug Market size is expected to reach USD 18.76 billion.

North America Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)